Profile data is unavailable for this security.
About the company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
- Revenue in USD (TTM)16.02m
- Net income in USD5.55m
- Incorporated2004
- Employees12.00
- LocationKiora Pharmaceuticals Inc332 ENCINITAS BOULEVARD, SUITE 102ENCINITAS 92024United StatesUSA
- Phone+1 (781) 788-8869
- Fax+1 (302) 636-5454
- Websitehttps://kiorapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jaguar Health Inc | 10.48m | -37.74m | 9.10m | 49.00 | -- | 0.7539 | -- | 0.8683 | -19.89 | -19.89 | 2.76 | 1.54 | 0.2018 | 0.231 | 7.17 | 213,877.50 | -73.81 | -95.29 | -106.50 | -163.54 | 80.10 | 67.28 | -365.71 | -522.28 | 1.36 | -3.22 | 0.6802 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Yubo International Biotech Ltd | 25.78k | -2.00m | 9.71m | 18.00 | -- | -- | -- | 376.47 | -0.0167 | -0.0167 | 0.0002 | -0.0261 | 0.0145 | 0.0467 | 0.1935 | 1,432.22 | -120.65 | -- | -- | -- | 80.41 | -- | -8,325.41 | -- | 0.1598 | -17,544.82 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -70.87m | 9.71m | 48.00 | -- | 0.608 | -- | -- | -15.59 | -15.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -74.80 | -- | -83.22 | -- | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| BioCardia Inc | 71.00k | -7.72m | 9.79m | 16.00 | -- | 3.51 | -- | 137.85 | -4.22 | -4.22 | 0.036 | 0.6086 | 0.0142 | -- | 1.25 | 4,437.50 | -154.22 | -107.34 | -401.77 | -154.17 | -- | -- | -10,876.06 | -1,779.24 | -- | -- | 0.00 | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 5.55m | 9.93m | 12.00 | 5.41 | 0.3308 | 1.78 | 0.62 | -0.5993 | -0.5993 | 4.89 | 10.01 | 0.5889 | -- | 9.18 | 1,335,000.00 | 20.40 | -70.52 | 22.75 | -81.86 | -- | -- | 34.64 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 377.00k | -6.17m | 10.00m | 11.00 | -- | 1.00 | -- | 26.52 | -0.7135 | -0.7135 | 0.0546 | 1.44 | 0.0266 | -- | 3.69 | 34,272.73 | -43.49 | -192.11 | -53.99 | -329.32 | 79.04 | -- | -1,636.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Imunon Inc | 0.00 | -19.45m | 10.05m | 33.00 | -- | 1.23 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5649 | 0.00 | -- | -- | 0.00 | -99.63 | -50.18 | -137.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Vaccinex Inc | 388.00k | -18.58m | 10.06m | 37.00 | -- | -- | -- | 25.93 | -12.15 | -12.15 | 0.2512 | -0.5081 | 0.1047 | -- | 0.4046 | 10,486.49 | -501.27 | -262.29 | -- | -- | -- | -- | -4,787.89 | -4,257.17 | -- | -49.48 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Dominari Holdings Inc | 12.59m | -22.69m | 10.23m | 26.00 | -- | 0.2673 | -- | 0.8126 | -3.85 | -3.85 | 2.11 | 6.10 | 0.2361 | -- | 3.80 | 484,192.30 | -42.55 | -26.82 | -44.27 | -27.45 | -- | -- | -180.22 | -3,353.52 | -- | -4.83 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.66m | 10.31m | 22.00 | -- | 1.17 | -- | -- | -0.0115 | -0.0115 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -17.29 | -25.03 | -39.98 | -48.76 | -- | -- | -- | -1,692.93 | -- | -0.5009 | 0.614 | -- | -- | -- | -255.12 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 10.46m | 18.00 | -- | 0.1166 | -- | 4.27 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 10.46m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.89m | 10.66m | 7.00 | -- | 1.77 | -- | -- | -1.72 | -1.72 | 0.00 | 0.5887 | 0.00 | -- | -- | 0.00 | -114.42 | -66.55 | -138.96 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 10.73m | 75.00 | 0.0005 | 0.00003 | 1.98 | 0.603 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Kiora Pharmaceuticals Inc's reporting currency: US Dollar USD
49.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 30 Sep 2024 | 255.56k | 8.60% |
| Rosalind Advisors, Inc.as of 30 Sep 2024 | 255.56k | 8.60% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 211.11k | 7.11% |
| Stonepine Capital Management LLCas of 30 Sep 2024 | 202.40k | 6.81% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 196.55k | 6.62% |
| Alyeska Investment Group LPas of 30 Sep 2024 | 180.78k | 6.09% |
| Velan Capital Investment Management LPas of 30 Sep 2024 | 122.22k | 4.11% |
| Geode Capital Management LLCas of 30 Sep 2024 | 14.48k | 0.49% |
| G1 Execution Services LLCas of 30 Sep 2024 | 11.38k | 0.38% |
| Citadel Securities LLCas of 30 Sep 2024 | 10.11k | 0.34% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
